Jump to content

Interleukin 2: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 675657432 by Waldo is Somewhere (talk)
consistent citation formatting
Line 4: Line 4:
== Signaling pathway ==
== Signaling pathway ==


IL-2 is a member of a [[cytokine]] family, each member of which has a [[Helix bundle#Four-helix bundles|four alpha helix bundle]]; the family also includes [[Interleukin-4|IL-4]], [[Interleukin 7|IL-7]], [[Interleukin 9|IL-9]], [[Interleukin 15|IL-15]] and [[Interleukin 21|IL-21]]. IL-2 signals through the [[IL-2 receptor]], a complex consisting of three chains, termed alpha, beta and [[Common gamma chain|gamma]]. The gamma chain is shared by all members of this family of cytokine receptors.<ref name="Liao_2011">{{cite journal | vauthors = Liao W, Lin JX, Leonard WJ | title = IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation | journal = Curr. Opin. Immunol. | volume = 23 | issue = 5 | pages = 598–604 | year = 2011 | pmid = 21889323 | pmc = 3405730 | doi = 10.1016/j.coi.2011.08.003 }}</ref>
IL-2 is a member of a [[cytokine]] family, each member of which has a [[Helix bundle#Four-helix bundles|four alpha helix bundle]]; the family also includes [[Interleukin-4|IL-4]], [[Interleukin 7|IL-7]], [[Interleukin 9|IL-9]], [[Interleukin 15|IL-15]] and [[Interleukin 21|IL-21]]. IL-2 signals through the [[IL-2 receptor]], a complex consisting of three chains, termed alpha, beta and [[Common gamma chain|gamma]]. The gamma chain is shared by all members of this family of cytokine receptors.<ref name="Liao_2011">{{cite journal | vauthors = Liao W, Lin JX, Leonard WJ | title = IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation | journal = Current Opinion in Immunology | volume = 23 | issue = 5 | pages = 598–604 | date = Oct 2011 | pmid = 21889323 | pmc = 3405730 | doi = 10.1016/j.coi.2011.08.003 }}</ref>


The IL-2 Receptor (IL-2R) α subunit has low affinity for its ligand but has the ability (when bound to the β and ϒ subunit) to increase the IL-2R affinity 100-fold. Heterodimerization of the β and ϒ subunits of IL-2R is essential for the signalling in T cells.<ref name="Gaffen_2004">{{cite journal | vauthors = Gaffen SL, Liu KD | title = Overview of interleukin-2 function, production and clinical applications | journal = Cytokine | volume = 28 | issue = 3 | pages = 109–23 | year = 2004 | pmid = 15473953 | doi = 10.1016/j.cyto.2004.06.010 }}</ref>
The IL-2 Receptor (IL-2R) α subunit has low affinity for its ligand but has the ability (when bound to the β and ϒ subunit) to increase the IL-2R affinity 100-fold. Heterodimerization of the β and ϒ subunits of IL-2R is essential for the signalling in T cells.<ref name="Gaffen_2004">{{cite journal | vauthors = Gaffen SL, Liu KD | title = Overview of interleukin-2 function, production and clinical applications | journal = Cytokine | volume = 28 | issue = 3 | pages = 109–23 | date = Nov 2004 | pmid = 15473953 | doi = 10.1016/j.cyto.2004.06.010 }}</ref>


== Function ==
== Function ==


IL-2 has key roles in key functions of the immune system, [[Central tolerance|tolerance]] and [[Immunity (medical)|immunity]], primarily via its direct effects on [[T cells]]. In the [[thymus]], where T cells mature, it prevents [[autoimmune diseases]] by promoting the [[Cellular differentiation|differentiation]] of certain immature T cells into [[regulatory T cells]], which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 also promotes the differentiation of T cells into [[effector T cells]] and into [[memory T cells]] when the initial T cell is also stimulated by an [[antigen]], thus helping the body fight off infections.<ref name="Liao_2011"/> Its expression and secretion is tightly regulated and functions as part of both transient positive and negative [[Feedback#Biology|feedback loops]] in mounting immune responses and tamping them down. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it also has a key role in enduring [[cell-mediated immunity]].<ref name="Liao_2011"/><ref name=Malek_2010>{{cite journal | vauthors = Malek TR, Castro I | title = Interleukin-2 receptor signaling: at the interface between tolerance and immunity | journal = Immunity | volume = 33 | issue = 2 | pages = 153–65 | year = 2010 | pmid = 20732639 | pmc = 2946796 | doi = 10.1016/j.immuni.2010.08.004 }}</ref>
IL-2 has key roles in key functions of the immune system, [[Central tolerance|tolerance]] and [[Immunity (medical)|immunity]], primarily via its direct effects on [[T cells]]. In the [[thymus]], where T cells mature, it prevents [[autoimmune diseases]] by promoting the [[Cellular differentiation|differentiation]] of certain immature T cells into [[regulatory T cells]], which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 also promotes the differentiation of T cells into [[effector T cells]] and into [[memory T cells]] when the initial T cell is also stimulated by an [[antigen]], thus helping the body fight off infections.<ref name="Liao_2011"/> Its expression and secretion is tightly regulated and functions as part of both transient positive and negative [[Feedback#Biology|feedback loops]] in mounting immune responses and tamping them down. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it also has a key role in enduring [[cell-mediated immunity]].<ref name="Liao_2011"/><ref name=Malek_2010>{{cite journal | vauthors = Malek TR, Castro I | title = Interleukin-2 receptor signaling: at the interface between tolerance and immunity | journal = Immunity | volume = 33 | issue = 2 | pages = 153–65 | date = Aug 2010 | pmid = 20732639 | pmc = 2946796 | doi = 10.1016/j.immuni.2010.08.004 }}</ref>


===Role in diseases===
== Role in disease ==


While the causes of [[pruritus|itchiness]] are poorly understood, there is some evidence that IL-2 may be involved in itchy [[psoriasis]].<ref name="pmid18288273">{{cite journal | vauthors = Reich A, Szepietowski JC | title = Mediators of pruritus in psoriasis | journal = Mediators Inflamm. | volume = 2007 | issue = | pages = 64727 | year = 2007 | pmid = 18288273 | pmc = 2221678 | doi = 10.1155/2007/64727d }}</ref>
While the causes of [[pruritus|itchiness]] are poorly understood, there is some evidence that IL-2 may be involved in itchy [[psoriasis]].<ref name="pmid18288273">{{cite journal | vauthors = Reich A, Szepietowski JC | title = Mediators of pruritus in psoriasis | journal = Mediators of Inflammation | volume = 2007 | issue = | pages = 64727 | year = 2007 | pmid = 18288273 | pmc = 2221678 | doi = 10.1155/2007/64727d }}</ref>


== Medical use ==
== Medical use ==

IL-2 is manufactured using [[recombinant DNA]] technology and is marketed as a [[Biologic medical product|protein therapeutic]] called aldesleukin (branded as Proleukin) by Prometheus Laboratories, Inc. It has been approved by the [[Food and Drug Administration]] (FDA) and in several European countries for the treatment of cancers (malignant melanoma, renal cell cancer) in large intermittent doses and has been extensively used in continuous doses.<ref name="pmid18031103">{{cite journal | vauthors = Noble S, Goa KL | title = Aldesleukin (recombinant interleukin-2) | journal = BioDrugs | volume = 7 | issue = 5 | pages = 394–422 | year = 1997 | pmid = 18031103 | doi = 10.2165/00063030-199707050-00007 }}</ref><ref name="pmid19544689">{{cite journal | vauthors = Bhatia S, Tykodi SS, Thompson JA | title = Treatment of metastatic melanoma: an overview | journal = Oncology (Williston Park, N.Y.) | volume = 23 | issue = 6 | pages = 488–96 | year = 2009 | pmid = 19544689 | pmc = 2737459 | doi = | url = http://www.cancernetwork.com/oncology-journal/treatment-metastatic-melanoma-overview }}</ref><ref name=Pollack_1990/>
IL-2 is manufactured using [[recombinant DNA]] technology and is marketed as a [[Biologic medical product|protein therapeutic]] called aldesleukin (branded as Proleukin) by Prometheus Laboratories, Inc. It has been approved by the [[Food and Drug Administration]] (FDA) and in several European countries for the treatment of cancers (malignant melanoma, renal cell cancer) in large intermittent doses and has been extensively used in continuous doses.<ref name="pmid18031103">{{cite journal | vauthors = Noble S, Goa KL | title = Aldesleukin (recombinant interleukin-2) | journal = BioDrugs | volume = 7 | issue = 5 | pages = 394–422 | date = May 1997 | pmid = 18031103 | doi = 10.2165/00063030-199707050-00007 }}</ref><ref name="pmid19544689">{{cite journal | vauthors = Bhatia S, Tykodi SS, Thompson JA | title = Treatment of metastatic melanoma: an overview | journal = Oncology | volume = 23 | issue = 6 | pages = 488–96 | date = May 2009 | pmid = 19544689 | pmc = 2737459 | doi = | url = http://www.cancernetwork.com/oncology-journal/treatment-metastatic-melanoma-overview }}</ref><ref name=Pollack_1990/>


The Hong Kong company, Shenzhen Neptunus Interlng-H, sells a recombinant IL-2 called Interking, with a serine at residue 125.<ref>Bloombert BusinessWeek. Last updated March 3, 2014 [http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=8329:HK Shenzhen Neptunus Interlng-H ]</ref>
The Hong Kong company, Shenzhen Neptunus Interlng-H, sells a recombinant IL-2 called Interking, with a serine at residue 125.<ref>Bloombert BusinessWeek. Last updated March 3, 2014 [http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=8329:HK Shenzhen Neptunus Interlng-H ]</ref>
Line 29: Line 30:


===Toxicity===
===Toxicity===
IL-2 has a narrow [[therapeutic window]], and the level of dosing usually determines the severity of the side effects.<ref name="pmid19009549">{{cite journal | vauthors = Shaker MA, Younes HM | title = Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy | journal = J Pharm Sci | volume = 98 | issue = 7 | pages = 2268–98 | year = 2009 | pmid = 19009549 | doi = 10.1002/jps.21596 }}</ref>
IL-2 has a narrow [[therapeutic window]], and the level of dosing usually determines the severity of the side effects.<ref name="pmid19009549">{{cite journal | vauthors = Shaker MA, Younes HM | title = Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy | journal = Journal of Pharmaceutical Sciences | volume = 98 | issue = 7 | pages = 2268–98 | date = Jul 2009 | pmid = 19009549 | doi = 10.1002/jps.21596 }}</ref>


Some Common Side Effects:<ref name="American Cancer Society" />
Some Common Side Effects:<ref name="American Cancer Society" />
Line 51: Line 52:
According to an immunology textbook: "IL-2 is particularly important historically, as it is the first type I cytokine that was cloned, the first type I cytokine for which a receptor component was cloned, and was the first short-chain type I cytokine whose receptor structure was solved. Many general principles have been derived from studies of this cytokine, including its being the first cytokine demonstrated to act in a growth factor–like fashion through specific high-affinity receptors, analogous to the growth factors being studied by endocrinologists and biochemists".<ref name=Leonard/>{{rp|712}}
According to an immunology textbook: "IL-2 is particularly important historically, as it is the first type I cytokine that was cloned, the first type I cytokine for which a receptor component was cloned, and was the first short-chain type I cytokine whose receptor structure was solved. Many general principles have been derived from studies of this cytokine, including its being the first cytokine demonstrated to act in a growth factor–like fashion through specific high-affinity receptors, analogous to the growth factors being studied by endocrinologists and biochemists".<ref name=Leonard/>{{rp|712}}


In the mid-1960s, studies reported "activities" in leukocyte conditioned media that promoted [[lymphocyte]] proliferation.<ref name="pmid20074271">{{cite journal | vauthors = Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT | title = Pharmacologic administration of interleukin-2 | journal = Ann. N. Y. Acad. Sci. | volume = 1182 | issue = | pages = 14–27 | year = 2009 | pmid = 20074271 | doi = 10.1111/j.1749-6632.2009.05160.x }}</ref>{{rp|16}} In the mid-1970s, it was discovered that T-cells could be selectively proliferated when normal human bone marrow cells were cultured in conditioned medium obtained from [[phytohemagglutinin]]-stimulated normal human lymphocytes.<ref name=Leonard>Warren J. Leonard. Type I Cytokines and Interferons and Their Receptors. Chapter 23 in Fundamental Immunology, 6th ed. Editor, William E. Paul. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins, c2008. ISBN 9780781765190</ref>{{rp|712}} The key factor was isolated from cultured mouse cells in 1979 and from cultured human cells in 1980.<ref name="pmid6980256">{{cite journal | vauthors = Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA | title = Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity | journal = J. Exp. Med. | volume = 156 | issue = 2 | pages = 454–64 | year = 1982 | pmid = 6980256 | pmc = 2186775 | doi = 10.1084/jem.156.2.454 }}</ref> The gene for human IL-2 was cloned in 1982 after an intense competition.<ref name=CetusHist>Paul Rabinow. Making PCR: A Story of Biotechnology. University of Chicago Press, 1996 ISBN 978-0226701479</ref>{{rp|76}}
In the mid-1960s, studies reported "activities" in leukocyte conditioned media that promoted [[lymphocyte]] proliferation.<ref name="pmid20074271">{{cite journal | vauthors = Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT | title = Pharmacologic administration of interleukin-2 | journal = Annals of the New York Academy of Sciences | volume = 1182 | issue = | pages = 14–27 | date = Dec 2009 | pmid = 20074271 | doi = 10.1111/j.1749-6632.2009.05160.x }}</ref>{{rp|16}} In the mid-1970s, it was discovered that T-cells could be selectively proliferated when normal human bone marrow cells were cultured in conditioned medium obtained from [[phytohemagglutinin]]-stimulated normal human lymphocytes.<ref name=Leonard>Warren J. Leonard. Type I Cytokines and Interferons and Their Receptors. Chapter 23 in Fundamental Immunology, 6th ed. Editor, William E. Paul. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins, c2008. ISBN 9780781765190</ref>{{rp|712}} The key factor was isolated from cultured mouse cells in 1979 and from cultured human cells in 1980.<ref name="pmid6980256">{{cite journal | vauthors = Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA | title = Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity | journal = The Journal of Experimental Medicine | volume = 156 | issue = 2 | pages = 454–64 | date = Aug 1982 | pmid = 6980256 | pmc = 2186775 | doi = 10.1084/jem.156.2.454 }}</ref> The gene for human IL-2 was cloned in 1982 after an intense competition.<ref name=CetusHist>Paul Rabinow. Making PCR: A Story of Biotechnology. University of Chicago Press, 1996 ISBN 978-0226701479</ref>{{rp|76}}


Commercial activity to bring an IL-2 drug to market was intense in the 1980s and 90s. By 1983 [[Cetus Corporation]] had created a proprietary recombinant version of IL2 (aldesleukin, later called Proleukin), with the alanine removed from its N-terminal and residue 125 replaced with serine.<ref name=CetusHist/>{{rp|76–77}}<ref>Hugo Almeida. [http://www.scielo.br/pdf/bjps/v47n2/v47n2a02.pdf Drugs obtained by biotechnology processing] Brazilian Journal of Pharmaceutical Sciences apr/jun 2011 47(2):199-207</ref>{{rp|201}}<ref name="Whittington_1993"/> [[Amgen]] later entered the field with its own proprietary, mutated, recombinant protein and Cetus and Amgen were soon competing scientifically and in the courts; Cetus won the legal battles and forced Amgen out of the field.<ref name=CetusHist/>{{rp|151}} By 1990 Cetus had gotten aldesleukin approved in nine European countries but in that year, the U.S. [[Food and Drug Administration]] (FDA) refused to approve Cetus' application to market IL-2.<ref name="Pollack_1990">{{cite web | url = http://www.nytimes.com/1990/07/31/business/cetus-drug-is-blocked-by-fda.html | title = Cetus Drug Is Blocked By F.D.A. | work = New York Times | author = Pollack A | date = July 31, 1990 }} This source mentions approval in 9 European countries.</ref> The failure led to the collapse of Cetus, and in 1991 the company was sold to [[Chiron Corporation]].<ref name="Pollack_1991">{{cite web | url = http://www.nytimes.com/1991/07/23/business/2-biotech-pioneers-to-merge.html | title = 2 Biotech Pioneers To Merge | work = New York Times | date = July 23, 1991 }}</ref><ref name="Lehrman_1992">{{cite web | url = http://www.the-scientist.com/?articles.view/articleNo/12113/title/Cetus--A-Collision-Course-With-Failure/ | title = Cetus: A Collision Course With Failure | work = The Scientist Magazine | author = Lehrman S | date = January 20, 1992 }}</ref> Chiron continued the development of IL-2, which was finally approved by the FDA as Proleukin for metastatic [[renal carcinoma]] in 1992.<ref name="pmid12469934">{{cite journal | vauthors = Dutcher J | title = Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma | journal = Oncology (Williston Park, N.Y.) | volume = 16 | issue = 11 Suppl 13 | pages = 4–10 | year = 2002 | pmid = 12469934 | doi = }}</ref> By 1993 aldesleukin was the only approved version of IL-2, but Roche was also developing a proprietary, modified, recombinant IL-2 called teceleukin, with a methionine added at is N-terminal, and Glaxo was developing a version called bioleukin, with a methionine added at is N-terminal and residue 125 replaced with alanine, and dozens of clinical trials had been conducted of recombinant or purified IL-2, alone, in combination with other drugs, or using cell therapies, in which cells were taken from patients, activated with IL-2, then infused back into the patients.<ref name="Whittington_1993">{{cite journal | vauthors = Whittington R, Faulds D | title = Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer | journal = Drugs | volume = 46 | issue = 3 | pages = 446–514 | date = September 1993 | pmid = 7693434 | doi = 10.2165/00003495-199346030-00009 }}</ref><ref name="urlKEGG DRUG: D02749">{{cite web | url = http://www.genome.jp/dbget-bin/www_bget?dr:D02749 | title = D02749 (Teceleukin) | format = | work = KEGG drug | accessdate = }}</ref> Novartis acquired Chiron in 2006<ref name="urlChiron shareholders approve Novartis deal - SWI swissinfo.ch">{{cite web | url = http://www.swissinfo.ch/eng/chiron-shareholders-approve-novartis-deal/5134216 | title = Chiron shareholders approve Novartis deal | work = SWI swissinfo.ch | date = Apr 19, 2006 }}</ref> and sold the aldesleukin business to Prometheus Laboratories in 2010.<ref name="urlNovartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal">{{cite web | url = http://www.thepharmaletter.com/article/novartis-sells-rights-to-proleukin-in-the-usa-to-prometheus-gets-license-for-vaccine-from-iig-and-pleads-guilty-over-trileptal | title = Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal | work = Pharmaletter | date = January 27, 2010 }}</ref>
Commercial activity to bring an IL-2 drug to market was intense in the 1980s and 90s. By 1983 [[Cetus Corporation]] had created a proprietary recombinant version of IL2 (aldesleukin, later called Proleukin), with the alanine removed from its N-terminal and residue 125 replaced with serine.<ref name=CetusHist/>{{rp|76–77}}<ref>Hugo Almeida. [http://www.scielo.br/pdf/bjps/v47n2/v47n2a02.pdf Drugs obtained by biotechnology processing] Brazilian Journal of Pharmaceutical Sciences apr/jun 2011 47(2):199-207</ref>{{rp|201}}<ref name="Whittington_1993"/> [[Amgen]] later entered the field with its own proprietary, mutated, recombinant protein and Cetus and Amgen were soon competing scientifically and in the courts; Cetus won the legal battles and forced Amgen out of the field.<ref name=CetusHist/>{{rp|151}} By 1990 Cetus had gotten aldesleukin approved in nine European countries but in that year, the U.S. [[Food and Drug Administration]] (FDA) refused to approve Cetus' application to market IL-2.<ref name="Pollack_1990">{{cite web | url = http://www.nytimes.com/1990/07/31/business/cetus-drug-is-blocked-by-fda.html | title = Cetus Drug Is Blocked By F.D.A. | work = New York Times | author = Pollack A | date = July 31, 1990 }} This source mentions approval in 9 European countries.</ref> The failure led to the collapse of Cetus, and in 1991 the company was sold to [[Chiron Corporation]].<ref name="Pollack_1991">{{cite web | url = http://www.nytimes.com/1991/07/23/business/2-biotech-pioneers-to-merge.html | title = 2 Biotech Pioneers To Merge | work = New York Times | date = July 23, 1991 }}</ref><ref name="Lehrman_1992">{{cite web | url = http://www.the-scientist.com/?articles.view/articleNo/12113/title/Cetus--A-Collision-Course-With-Failure/ | title = Cetus: A Collision Course With Failure | work = The Scientist Magazine | author = Lehrman S | date = January 20, 1992 }}</ref> Chiron continued the development of IL-2, which was finally approved by the FDA as Proleukin for metastatic [[renal carcinoma]] in 1992.<ref name="pmid12469934">{{cite journal | vauthors = Dutcher J | title = Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma | journal = Oncology | volume = 16 | issue = 11 Suppl 13 | pages = 4–10 | date = Nov 2002 | pmid = 12469934 | doi = }}</ref> By 1993 aldesleukin was the only approved version of IL-2, but Roche was also developing a proprietary, modified, recombinant IL-2 called teceleukin, with a methionine added at is N-terminal, and Glaxo was developing a version called bioleukin, with a methionine added at is N-terminal and residue 125 replaced with alanine, and dozens of clinical trials had been conducted of recombinant or purified IL-2, alone, in combination with other drugs, or using cell therapies, in which cells were taken from patients, activated with IL-2, then infused back into the patients.<ref name="Whittington_1993">{{cite journal | vauthors = Whittington R, Faulds D | title = Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer | journal = Drugs | volume = 46 | issue = 3 | pages = 446–514 | date = Sep 1993 | pmid = 7693434 | doi = 10.2165/00003495-199346030-00009 }}</ref><ref name="urlKEGG DRUG: D02749">{{cite web | url = http://www.genome.jp/dbget-bin/www_bget?dr:D02749 | title = D02749 (Teceleukin) | format = | work = KEGG drug | accessdate = }}</ref> Novartis acquired Chiron in 2006<ref name="urlChiron shareholders approve Novartis deal - SWI swissinfo.ch">{{cite web | url = http://www.swissinfo.ch/eng/chiron-shareholders-approve-novartis-deal/5134216 | title = Chiron shareholders approve Novartis deal | work = SWI swissinfo.ch | date = Apr 19, 2006 }}</ref> and sold the aldesleukin business to Prometheus Laboratories in 2010.<ref name="urlNovartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal">{{cite web | url = http://www.thepharmaletter.com/article/novartis-sells-rights-to-proleukin-in-the-usa-to-prometheus-gets-license-for-vaccine-from-iig-and-pleads-guilty-over-trileptal | title = Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal | work = Pharmaletter | date = January 27, 2010 }}</ref>

<ref name="Intralesional_IL_2">{{{cite journal |author = Shi VY, Tran K, Patel F, Leventhal J,Konia T, Fung MA, Wilken R,Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E | title = 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series | journal = JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY  | doi = 10.1016/j.jaad.2015.06.060.}}</ref>


== References ==
== References ==
{{Reflist|2}}
{{reflist|33em}}



== External links ==
== External links ==

Revision as of 21:56, 11 August 2015

Template:PBB Interleukin 2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.

Signaling pathway

IL-2 is a member of a cytokine family, each member of which has a four alpha helix bundle; the family also includes IL-4, IL-7, IL-9, IL-15 and IL-21. IL-2 signals through the IL-2 receptor, a complex consisting of three chains, termed alpha, beta and gamma. The gamma chain is shared by all members of this family of cytokine receptors.[1]

The IL-2 Receptor (IL-2R) α subunit has low affinity for its ligand but has the ability (when bound to the β and ϒ subunit) to increase the IL-2R affinity 100-fold. Heterodimerization of the β and ϒ subunits of IL-2R is essential for the signalling in T cells.[2]

Function

IL-2 has key roles in key functions of the immune system, tolerance and immunity, primarily via its direct effects on T cells. In the thymus, where T cells mature, it prevents autoimmune diseases by promoting the differentiation of certain immature T cells into regulatory T cells, which suppress other T cells that are otherwise primed to attack normal healthy cells in the body. IL-2 also promotes the differentiation of T cells into effector T cells and into memory T cells when the initial T cell is also stimulated by an antigen, thus helping the body fight off infections.[1] Its expression and secretion is tightly regulated and functions as part of both transient positive and negative feedback loops in mounting immune responses and tamping them down. Through its role in the development of T cell immunologic memory, which depends upon the expansion of the number and function of antigen-selected T cell clones, it also has a key role in enduring cell-mediated immunity.[1][3]

Role in disease

While the causes of itchiness are poorly understood, there is some evidence that IL-2 may be involved in itchy psoriasis.[4]

Medical use

IL-2 is manufactured using recombinant DNA technology and is marketed as a protein therapeutic called aldesleukin (branded as Proleukin) by Prometheus Laboratories, Inc. It has been approved by the Food and Drug Administration (FDA) and in several European countries for the treatment of cancers (malignant melanoma, renal cell cancer) in large intermittent doses and has been extensively used in continuous doses.[5][6][7]

The Hong Kong company, Shenzhen Neptunus Interlng-H, sells a recombinant IL-2 called Interking, with a serine at residue 125.[8]

Eisai sells a drug called Denileukin diftitox (trade name Ontak), which is recombinant protein combining IL-2 and Diphtheria toxin. This drug binds to IL-2 receptors and introduces the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express the IL-2 receptor, so denileukin diftitox can kill them. In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[9]

Dosages

There are different dosages of IL-2 across the United States and across the world being used to treat patients. The efficiency and side effects of different dosages is often a point of disagreement. Usually, in the U.S., the higher dosage option is used, depending on the cancer, response to treatment, and general health of the patient. Patients are typically given the high dosages for five consecutive days, three times a day, for fifteen minutes. The patient is given approximately 10 days to recover between treatment dosages. The IL-2 is delivered through an IV for this type of dosing, and hospitalization/intensive care is required throughout due to the side effects.[10]

Another dosage option is in a lower regimen used by some doctors. It can be an injection of IL-2 under the skin at home or doctor’s office. It is also possible to get this dosage through an IV in the hospital over 1–3 days, similar to and often including the delivery of chemotherapy.[10]

Toxicity

IL-2 has a narrow therapeutic window, and the level of dosing usually determines the severity of the side effects.[11]

Some Common Side Effects:[10]

More serious and dangerous side effects sometimes are seen, such as capillary leak syndrome, breathing problems, serious infections, seizures, allergic reactions, heart problems or a variety of other possible complications.[10]

Clinical research

IL-2 has been in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of large doses of IL-2 given every 6–8 weeks in HIV therapy, similar to its use in cancer therapy, was found to be ineffective in preventing progression to an AIDS diagnosis in two large clinical trials published in 2009.[12]

Discovery and development

According to an immunology textbook: "IL-2 is particularly important historically, as it is the first type I cytokine that was cloned, the first type I cytokine for which a receptor component was cloned, and was the first short-chain type I cytokine whose receptor structure was solved. Many general principles have been derived from studies of this cytokine, including its being the first cytokine demonstrated to act in a growth factor–like fashion through specific high-affinity receptors, analogous to the growth factors being studied by endocrinologists and biochemists".[13]: 712 

In the mid-1960s, studies reported "activities" in leukocyte conditioned media that promoted lymphocyte proliferation.[14]: 16  In the mid-1970s, it was discovered that T-cells could be selectively proliferated when normal human bone marrow cells were cultured in conditioned medium obtained from phytohemagglutinin-stimulated normal human lymphocytes.[13]: 712  The key factor was isolated from cultured mouse cells in 1979 and from cultured human cells in 1980.[15] The gene for human IL-2 was cloned in 1982 after an intense competition.[16]: 76 

Commercial activity to bring an IL-2 drug to market was intense in the 1980s and 90s. By 1983 Cetus Corporation had created a proprietary recombinant version of IL2 (aldesleukin, later called Proleukin), with the alanine removed from its N-terminal and residue 125 replaced with serine.[16]: 76–77 [17]: 201 [18] Amgen later entered the field with its own proprietary, mutated, recombinant protein and Cetus and Amgen were soon competing scientifically and in the courts; Cetus won the legal battles and forced Amgen out of the field.[16]: 151  By 1990 Cetus had gotten aldesleukin approved in nine European countries but in that year, the U.S. Food and Drug Administration (FDA) refused to approve Cetus' application to market IL-2.[7] The failure led to the collapse of Cetus, and in 1991 the company was sold to Chiron Corporation.[19][20] Chiron continued the development of IL-2, which was finally approved by the FDA as Proleukin for metastatic renal carcinoma in 1992.[21] By 1993 aldesleukin was the only approved version of IL-2, but Roche was also developing a proprietary, modified, recombinant IL-2 called teceleukin, with a methionine added at is N-terminal, and Glaxo was developing a version called bioleukin, with a methionine added at is N-terminal and residue 125 replaced with alanine, and dozens of clinical trials had been conducted of recombinant or purified IL-2, alone, in combination with other drugs, or using cell therapies, in which cells were taken from patients, activated with IL-2, then infused back into the patients.[18][22] Novartis acquired Chiron in 2006[23] and sold the aldesleukin business to Prometheus Laboratories in 2010.[24]

[25]

References

  1. ^ a b c Liao W, Lin JX, Leonard WJ (Oct 2011). "IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation". Current Opinion in Immunology. 23 (5): 598–604. doi:10.1016/j.coi.2011.08.003. PMC 3405730. PMID 21889323.
  2. ^ Gaffen SL, Liu KD (Nov 2004). "Overview of interleukin-2 function, production and clinical applications". Cytokine. 28 (3): 109–23. doi:10.1016/j.cyto.2004.06.010. PMID 15473953.
  3. ^ Malek TR, Castro I (Aug 2010). "Interleukin-2 receptor signaling: at the interface between tolerance and immunity". Immunity. 33 (2): 153–65. doi:10.1016/j.immuni.2010.08.004. PMC 2946796. PMID 20732639.
  4. ^ Reich A, Szepietowski JC (2007). "Mediators of pruritus in psoriasis". Mediators of Inflammation. 2007: 64727. doi:10.1155/2007/64727d. PMC 2221678. PMID 18288273.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  5. ^ Noble S, Goa KL (May 1997). "Aldesleukin (recombinant interleukin-2)". BioDrugs. 7 (5): 394–422. doi:10.2165/00063030-199707050-00007. PMID 18031103.
  6. ^ Bhatia S, Tykodi SS, Thompson JA (May 2009). "Treatment of metastatic melanoma: an overview". Oncology. 23 (6): 488–96. PMC 2737459. PMID 19544689.
  7. ^ a b Pollack A (July 31, 1990). "Cetus Drug Is Blocked By F.D.A." New York Times. This source mentions approval in 9 European countries.
  8. ^ Bloombert BusinessWeek. Last updated March 3, 2014 Shenzhen Neptunus Interlng-H
  9. ^ FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events
  10. ^ a b c d American Cancer Society. Interleukin-2 (Aldesleukin). Date accessed: 07 Nov 10.
  11. ^ Shaker MA, Younes HM (Jul 2009). "Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy". Journal of Pharmaceutical Sciences. 98 (7): 2268–98. doi:10.1002/jps.21596. PMID 19009549.
  12. ^ "IL-2 Immunotherapy Fails to Benefit HIV-Infected Individuals Already Taking Antiretrovirals". News Release. National Institutes of Health (NIH). February 10, 2009.
  13. ^ a b Warren J. Leonard. Type I Cytokines and Interferons and Their Receptors. Chapter 23 in Fundamental Immunology, 6th ed. Editor, William E. Paul. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins, c2008. ISBN 9780781765190
  14. ^ Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT (Dec 2009). "Pharmacologic administration of interleukin-2". Annals of the New York Academy of Sciences. 1182: 14–27. doi:10.1111/j.1749-6632.2009.05160.x. PMID 20074271.
  15. ^ Welte K, Wang CY, Mertelsmann R, Venuta S, Feldman SP, Moore MA (Aug 1982). "Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity". The Journal of Experimental Medicine. 156 (2): 454–64. doi:10.1084/jem.156.2.454. PMC 2186775. PMID 6980256.
  16. ^ a b c Paul Rabinow. Making PCR: A Story of Biotechnology. University of Chicago Press, 1996 ISBN 978-0226701479
  17. ^ Hugo Almeida. Drugs obtained by biotechnology processing Brazilian Journal of Pharmaceutical Sciences apr/jun 2011 47(2):199-207
  18. ^ a b Whittington R, Faulds D (Sep 1993). "Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer". Drugs. 46 (3): 446–514. doi:10.2165/00003495-199346030-00009. PMID 7693434.
  19. ^ "2 Biotech Pioneers To Merge". New York Times. July 23, 1991.
  20. ^ Lehrman S (January 20, 1992). "Cetus: A Collision Course With Failure". The Scientist Magazine.
  21. ^ Dutcher J (Nov 2002). "Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma". Oncology. 16 (11 Suppl 13): 4–10. PMID 12469934.
  22. ^ "D02749 (Teceleukin)". KEGG drug.
  23. ^ "Chiron shareholders approve Novartis deal". SWI swissinfo.ch. Apr 19, 2006.
  24. ^ "Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal". Pharmaletter. January 27, 2010.
  25. ^ {Shi VY, Tran K, Patel F, Leventhal J,Konia T, Fung MA, Wilken R,Garcia MS, Fitzmaurice SD, Joo J, Monjazeb AM, Burrall BA, King B, Martinez S, Christensen SD, Maverakis E. "100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series". JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. doi:10.1016/j.jaad.2015.06.060. {{cite journal}}: Check |doi= value (help)CS1 maint: multiple names: authors list (link)


Wikimedia Commons has media related to Interleukin-2.

Template:Depressogenics

Retrieved from "https://en.wikipedia.org/w/index.php?title=Interleukin_2&oldid=675658386"